Discovery Teams

Medicinal Chemistry

Objective:
Support the WCNDD’s drug discovery efforts by providing comprehensive in vitro and in vivo ADME (Absorption, Distribution, Metabolism, and Excretion) services, including metabolic stability, protein binding, permeability, CYP inhibition, pharmacokinetics, and human dose prediction.

  • Establish a DMPK team with capabilities uncommon in academic settings, modeled after the structure and efficiency of a mid-sized biotech company.

  • Deliver full in vitro and in vivo ADME profiling to de-risk preclinical candidates and facilitate early “Go/No-Go” decisions.

  • Understand mechanisms of drug clearance and pharmacokinetic/pharmacodynamic (PK/PD) relationships to maximize on-target efficacy.

  • The primary goal of in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) studies is to evaluate the pharmacokinetic properties of drug candidates early in the development process. These studies help predict how a drug will behave in the human body, guide chemical optimization, and assess potential drug-drug interactions, ultimately aiding in the selection of viable candidates for further investigation.

    • HLM Stability Assay (NADPH Dependent and UDPGA Dependent)

    • S9 Stability Assay

    • Hepatocytes Stability Assay

    • AO/XO liability

    • Protein Binding (Plasma and Brain Homogenate)

    • MDCK-II-MDR1 permeability

    • CYP Inhibition Assay (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4)

    • CYP TDI and ki , kinact determination

    • Metabolite Identification (MetID) Assay (HLM or Hepatocytes)

  • The main aim of in vivo DMPK (Drug Metabolism and Pharmacokinetics) studies is to assess how a drug behaves within a living organism, typically animal models. These studies provide crucial insights into absorption, distribution, metabolism, and excretion profiles under physiological conditions, helping predict human pharmacokinetics and supporting dose selection and safety evaluations for clinical trials.

    • Rat IV PK PBL Cassette

    • Rat IV PO PK discrete studies

    • Rat/Mouse PO PBL exposure studies

    • NCA Analysis

    • PK/PD relationship studies (Rat and Mouse)

      • MED and MTD to establish therapeutic index

  • Liquid handling and robotization streamline workflows by automating repetitive tasks, such as sample preparation and reagent dispensing, reducing manual labor and minimizing errors. These technologies enable higher precision and consistency, allowing researchers to process larger sample volumes in less time. At the WCNDD, we use the following equipment.

    • Triple Quad 4500 mass spectrometers

    • Qtrap 5500 and 6500+ mass spectrometers

    • Sciex Automated MRM Discoverer software

    • Orbitrap Thermo Lumos Fusion mass spectrometer

    • Tecan Evos liquid handler

    • Agilent Bravo with BenchCel workstation

    • Beckman Echo 650 liquid handler

  • First-in-human dose prediction involves integrating data from preclinical studies to estimate a safe starting dose for clinical trials. This involves analyzing pharmacokinetics, pharmacodynamics, and toxicity profiles from in vitro and in vivo studies, and scaling doses to humans using allometric or physiological models.

    • Allometric scaling

    • IVIVE

Molecular Pharmacology and Biology

Objective:
Support the WCNDD’s drug discovery efforts by providing comprehensive in vitro and in vivo ADME (Absorption, Distribution, Metabolism, and Excretion) services, including metabolic stability, protein binding, permeability, CYP inhibition, pharmacokinetics, and human dose prediction.

  • Establish a DMPK team with capabilities uncommon in academic settings, modeled after the structure and efficiency of a mid-sized biotech company.

  • Deliver full in vitro and in vivo ADME profiling to de-risk preclinical candidates and facilitate early “Go/No-Go” decisions.

  • Understand mechanisms of drug clearance and pharmacokinetic/pharmacodynamic (PK/PD) relationships to maximize on-target efficacy.

  • The primary goal of in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) studies is to evaluate the pharmacokinetic properties of drug candidates early in the development process. These studies help predict how a drug will behave in the human body, guide chemical optimization, and assess potential drug-drug interactions, ultimately aiding in the selection of viable candidates for further investigation.

    • HLM Stability Assay (NADPH Dependent and UDPGA Dependent)

    • S9 Stability Assay

    • Hepatocytes Stability Assay

    • AO/XO liability

    • Protein Binding (Plasma and Brain Homogenate)

    • MDCK-II-MDR1 permeability

    • CYP Inhibition Assay (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4)

    • CYP TDI and ki , kinact determination

    • Metabolite Identification (MetID) Assay (HLM or Hepatocytes)

  • The main aim of in vivo DMPK (Drug Metabolism and Pharmacokinetics) studies is to assess how a drug behaves within a living organism, typically animal models. These studies provide crucial insights into absorption, distribution, metabolism, and excretion profiles under physiological conditions, helping predict human pharmacokinetics and supporting dose selection and safety evaluations for clinical trials.

    • Rat IV PK PBL Cassette

    • Rat IV PO PK discrete studies

    • Rat/Mouse PO PBL exposure studies

    • NCA Analysis

    • PK/PD relationship studies (Rat and Mouse)

      • MED and MTD to establish therapeutic index

  • Liquid handling and robotization streamline workflows by automating repetitive tasks, such as sample preparation and reagent dispensing, reducing manual labor and minimizing errors. These technologies enable higher precision and consistency, allowing researchers to process larger sample volumes in less time. At the WCNDD, we use the following equipment.

    • Triple Quad 4500 mass spectrometers

    • Qtrap 5500 and 6500+ mass spectrometers

    • Sciex Automated MRM Discoverer software

    • Orbitrap Thermo Lumos Fusion mass spectrometer

    • Tecan Evos liquid handler

    • Agilent Bravo with BenchCel workstation

    • Beckman Echo 650 liquid handler

  • First-in-human dose prediction involves integrating data from preclinical studies to estimate a safe starting dose for clinical trials. This involves analyzing pharmacokinetics, pharmacodynamics, and toxicity profiles from in vitro and in vivo studies, and scaling doses to humans using allometric or physiological models.

    • Allometric scaling

    • IVIVE

Drug Metabolism and Pharmacokinetics (DMPK) 

Objective:
Support the WCNDD’s drug discovery efforts by providing comprehensive in vitro and in vivo ADME (Absorption, Distribution, Metabolism, and Excretion) services, including metabolic stability, protein binding, permeability, CYP inhibition, pharmacokinetics, and human dose prediction.

  • Establish a DMPK team with capabilities uncommon in academic settings, modeled after the structure and efficiency of a mid-sized biotech company.

  • Deliver full in vitro and in vivo ADME profiling to de-risk preclinical candidates and facilitate early “Go/No-Go” decisions.

  • Understand mechanisms of drug clearance and pharmacokinetic/pharmacodynamic (PK/PD) relationships to maximize on-target efficacy.

  • The primary goal of in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) studies is to evaluate the pharmacokinetic properties of drug candidates early in the development process. These studies help predict how a drug will behave in the human body, guide chemical optimization, and assess potential drug-drug interactions, ultimately aiding in the selection of viable candidates for further investigation.

    • HLM Stability Assay (NADPH Dependent and UDPGA Dependent)

    • S9 Stability Assay

    • Hepatocytes Stability Assay

    • AO/XO liability

    • Protein Binding (Plasma and Brain Homogenate)

    • MDCK-II-MDR1 permeability

    • CYP Inhibition Assay (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4)

    • CYP TDI and ki , kinact determination

    • Metabolite Identification (MetID) Assay (HLM or Hepatocytes)

  • The main aim of in vivo DMPK (Drug Metabolism and Pharmacokinetics) studies is to assess how a drug behaves within a living organism, typically animal models. These studies provide crucial insights into absorption, distribution, metabolism, and excretion profiles under physiological conditions, helping predict human pharmacokinetics and supporting dose selection and safety evaluations for clinical trials.

    • Rat IV PK PBL Cassette

    • Rat IV PO PK discrete studies

    • Rat/Mouse PO PBL exposure studies

    • NCA Analysis

    • PK/PD relationship studies (Rat and Mouse)

      • MED and MTD to establish therapeutic index

  • Liquid handling and robotization streamline workflows by automating repetitive tasks, such as sample preparation and reagent dispensing, reducing manual labor and minimizing errors. These technologies enable higher precision and consistency, allowing researchers to process larger sample volumes in less time. At the WCNDD, we use the following equipment.

    • Triple Quad 4500 mass spectrometers

    • Qtrap 5500 and 6500+ mass spectrometers

    • Sciex Automated MRM Discoverer software

    • Orbitrap Thermo Lumos Fusion mass spectrometer

    • Tecan Evos liquid handler

    • Agilent Bravo with BenchCel workstation

    • Beckman Echo 650 liquid handler

  • First-in-human dose prediction involves integrating data from preclinical studies to estimate a safe starting dose for clinical trials. This involves analyzing pharmacokinetics, pharmacodynamics, and toxicity profiles from in vitro and in vivo studies, and scaling doses to humans using allometric or physiological models.

    • Allometric scaling

    • IVIVE

Behavioral Pharmacology

Objective:
Support the WCNDD’s drug discovery efforts by providing comprehensive in vitro and in vivo ADME (Absorption, Distribution, Metabolism, and Excretion) services, including metabolic stability, protein binding, permeability, CYP inhibition, pharmacokinetics, and human dose prediction.

  • Establish a DMPK team with capabilities uncommon in academic settings, modeled after the structure and efficiency of a mid-sized biotech company.

  • Deliver full in vitro and in vivo ADME profiling to de-risk preclinical candidates and facilitate early “Go/No-Go” decisions.

  • Understand mechanisms of drug clearance and pharmacokinetic/pharmacodynamic (PK/PD) relationships to maximize on-target efficacy.

  • The primary goal of in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) studies is to evaluate the pharmacokinetic properties of drug candidates early in the development process. These studies help predict how a drug will behave in the human body, guide chemical optimization, and assess potential drug-drug interactions, ultimately aiding in the selection of viable candidates for further investigation.

    • HLM Stability Assay (NADPH Dependent and UDPGA Dependent)

    • S9 Stability Assay

    • Hepatocytes Stability Assay

    • AO/XO liability

    • Protein Binding (Plasma and Brain Homogenate)

    • MDCK-II-MDR1 permeability

    • CYP Inhibition Assay (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4)

    • CYP TDI and ki , kinact determination

    • Metabolite Identification (MetID) Assay (HLM or Hepatocytes)

  • The main aim of in vivo DMPK (Drug Metabolism and Pharmacokinetics) studies is to assess how a drug behaves within a living organism, typically animal models. These studies provide crucial insights into absorption, distribution, metabolism, and excretion profiles under physiological conditions, helping predict human pharmacokinetics and supporting dose selection and safety evaluations for clinical trials.

    • Rat IV PK PBL Cassette

    • Rat IV PO PK discrete studies

    • Rat/Mouse PO PBL exposure studies

    • NCA Analysis

    • PK/PD relationship studies (Rat and Mouse)

      • MED and MTD to establish therapeutic index

  • Liquid handling and robotization streamline workflows by automating repetitive tasks, such as sample preparation and reagent dispensing, reducing manual labor and minimizing errors. These technologies enable higher precision and consistency, allowing researchers to process larger sample volumes in less time. At the WCNDD, we use the following equipment.

    • Triple Quad 4500 mass spectrometers

    • Qtrap 5500 and 6500+ mass spectrometers

    • Sciex Automated MRM Discoverer software

    • Orbitrap Thermo Lumos Fusion mass spectrometer

    • Tecan Evos liquid handler

    • Agilent Bravo with BenchCel workstation

    • Beckman Echo 650 liquid handler

  • First-in-human dose prediction involves integrating data from preclinical studies to estimate a safe starting dose for clinical trials. This involves analyzing pharmacokinetics, pharmacodynamics, and toxicity profiles from in vitro and in vivo studies, and scaling doses to humans using allometric or physiological models.

    • Allometric scaling

    • IVIVE